January 9, 2014
Posted January 22, 2016
CareFusion Corp agreed to pay $40.1 million to resolve False Claims Act allegations that the company paid kickbacks and promoted its ChloraPrep products for non-FDA approved uses. The allegations were first raised in a qui tam lawsuit filed under the whistleblower provisions of the False Claims Act. DOJ
Tagged in: Anti-Kickback and Stark, FCA Federal, Medical Devices and DME, Off-Label and Unapproved Use, Whistleblower Case,